N-Boc-5,6-methylenedioxyanthranilic acid | 181434-64-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: N-Boc-5,6-methylenedioxyanthranilic acid
• 英文别名: 5-[(2-Methylpropan-2-yl)oxycarbonylamino]-1,3-benzodioxole-4-carboxylic acid
• CAS: 181434-64-0
• 化学式: C₁₃H₁₅NO₆
• 分子量: 281.265
• InChiKey: VBTYDWRRYVWCKO-UHFFFAOYSA-N

物化性质

• 沸点：
  367.4±42.0 °C(Predicted)
• 密度：
  1.391±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  94.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-Boc-5,6-methylenedioxyanthranilic acid 在 盐酸 、 sodium hydride 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 methyl 5-(methylamino)-1,3-benzodioxole-4-carboxylate
  参考文献：
  名称：

  QUINOLINE DERIVATIVES

  摘要：

  公开号：

  EP1095021B1
• 作为产物：
  描述：

  3,4-亚甲二氧基苯胺 在 仲丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 20.5h， 生成 N-Boc-5,6-methylenedioxyanthranilic acid
  参考文献：
  名称：

  Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for Treatment of Autoimmune Disorders:  Structure−Activity Relationship

  摘要：

  Roquinimex-related 3-quinolinecarboxamide derivatives were prepared and evaluated for treatment of autoimmune disorders. The compounds were tested in mice for their inhibitory effects on disease development in the acute experimental autoimmune encephalomyelitis model and selected compounds in the beagle dog for induction of proinflammatory reaction. Structure-activity relationships are discussed. Compound 8c, laquinimod, showed improved potency and superior toxicological profile compared to the lead compound roquinimex (1b, Linomide) and was selected for clinical studies (currently in phase II).

  DOI：

  10.1021/jm031044w

文献信息

• BICYCLIC SUBSTITUTED HEXAHYDROBENZ(E)ISOINDOLE ALPHA-1- ADRENERGIC ANTAGONISTS
  申请人：Abbott Laboratories

  公开号：EP0805812B1

  公开（公告）日：2001-06-13
• US5792767A
  申请人：——

  公开号：US5792767A

  公开（公告）日：1998-08-11
• [EN] BICYCLIC SUBSTITUTED HEXAHYDROBENZ[E]ISOINDOLE ALPHA-1- ADRENERGIC ANTAGONISTS<br/>[FR] ANTAGONISTES ALPHA-1-ADRENERGIQUES BICYCLIQUES SUBSTITUES D'HEXAHYDROBENZ(E)ISOINDOLE
  申请人：ABBOTT LABORATORIES

  公开号：WO1996022991A1

  公开（公告）日：1996-08-01

  (EN) The present invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein W is a bicyclic heterocyclic ring system. The compounds are $g(a)-1 adrenergic antagonists and are useful in the treatment of BPH; also disclosed are $g(a)-1 antagonist compositions and a method for antagonizing $g(a)-1 receptors and treating BPH.(FR) La présente invention concerne un composé de formule (I) ainsi que ses sels pharmaceutiquement acceptables, W étant un noyau hétérocyclique bicyclique. Les composés sont des antagonistes $g(a)-1 adrénergiques et ils sont utiles dans le traitement de l'hyperplasie prostatique bénigne. L'invention concerne aussi des compositions antagonistes $g(a)-1 adrénergiques et un procédé servant à rendre antagonistes des récepteurs $g(a)-1 et à traiter l'hyperplasie prostatique bénigne.
• QUINOLINE DERIVATIVES
  申请人：Active Biotech AB

  公开号：EP1095021B1

  公开（公告）日：2003-09-17
• Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for Treatment of Autoimmune Disorders:  Structure−Activity Relationship
  作者：Stig Jönsson、Gunnar Andersson、Tomas Fex、Tomas Fristedt、Gunnar Hedlund、Karl Jansson、Lisbeth Abramo、Ingela Fritzson、Olga Pekarski、Anna Runström、Helena Sandin、Ingela Thuvesson、Anders Björk

  DOI：10.1021/jm031044w

  日期：2004.4.1

  Roquinimex-related 3-quinolinecarboxamide derivatives were prepared and evaluated for treatment of autoimmune disorders. The compounds were tested in mice for their inhibitory effects on disease development in the acute experimental autoimmune encephalomyelitis model and selected compounds in the beagle dog for induction of proinflammatory reaction. Structure-activity relationships are discussed. Compound 8c, laquinimod, showed improved potency and superior toxicological profile compared to the lead compound roquinimex (1b, Linomide) and was selected for clinical studies (currently in phase II).